Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) EPS (Basic) (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of EPS (Basic) data on record, last reported at -$3.62 in Q3 2025.

  • For Q3 2025, EPS (Basic) rose 84.04% year-over-year to -$3.62; the TTM value through Sep 2025 reached $390.66, up 102.58%, while the annual FY2024 figure was -$176.6, 98.8% up from the prior year.
  • EPS (Basic) reached -$3.62 in Q3 2025 per TNXP's latest filing, up from -$3.96 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $401.08 in Q4 2024 and bottomed at -$14576.8 in Q4 2023.
  • Average EPS (Basic) over 3 years is -$1355.2, with a median of -$19.28 recorded in 2024.
  • The widest YoY moves for EPS (Basic): up 102.75% in 2024, down 16589.1% in 2024.
  • A 3-year view of EPS (Basic) shows it stood at -$14576.8 in 2023, then surged by 102.75% to $401.08 in 2024, then plummeted by 100.9% to -$3.62 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$3.62 in Q3 2025, -$3.96 in Q2 2025, and -$2.84 in Q1 2025.